Literature DB >> 35181878

COVID-19 Lockdown Periods in 2020: Good Maintenance of Metabolic Control in Adults with Type 1 and Type 2 Diabetes.

B Hartmann1, S R Tittel2,3, M Femerling4, M Pfeifer5, S Meyhöfer3,6,7, K Lange8, S Milek9, L Stemler10, F Best11, R W Holl2,3.   

Abstract

During the COVID-19 pandemic, there were increased concerns about glycemic control in patients with diabetes. Therefore, we aimed to assess changes in diabetes management during the COVID-19 lockdown for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM) in Germany. We included data from 24,623 patients (age>18 years) with T1DM (N=6,975) or T2DM (N=17,648) with documented data in 2019 and 2020 from the multicenter Diabetes-Prospective Follow-up registry (DPV). We conducted a groupwise comparison of identical patients in 2019 and 2020 for different time periods of pandemia. Pairwise differences of continuous parameters of treatment modalities and metabolic outcome between 2019 and 2020 were adjusted for seasonality, age, and diabetes duration. We presented these outcomes as adjusted medians with 95% confidence intervals. Rates were compared using negative-binomial models, dichotomous outcomes were compared using logistic models. Models were additionally adjusted for age and diabetes duration. These outcomes were presented as least-square means with 95% confidence intervals, p-values of<.05 were considered significant.In participants with T1DM, CGI (combined glucose indicator) increased only by 0.11-0.12% in all time periods of 2020 compared to 2019 (all p<0.001) while BMI decreased slightly by -(0.09-0.10) kg/m² (p<0.0001). In participants with T2DM, HbA1c increased by 0.12%, while BMI decreased slightly by -(0.05-0.06) kg/m² (p<0.0001).During the COVID-19 lockdown period, patients with T1DM and T2DM experienced only clinically insignificant changes in glucose control or body weight. Despite lockdown restrictions, patients were able to maintain metabolic control. Thieme. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35181878     DOI: 10.1055/a-1743-2537

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.426


  2 in total

1.  The impact of the COVID-19 pandemic on glycaemic control in people with diabetes: A systematic review and meta-analysis.

Authors:  Lauren L O'Mahoney; Patrick J Highton; Laura Kudlek; Jessica Morgan; Rosie Lynch; Ella Schofield; Nayanika Sreejith; Ajay Kapur; Afolarin Otunla; Sven Kerneis; Olivia James; Karen Rees; Ffion Curtis; Kamlesh Khunti; Jamie Hartmann-Boyce
Journal:  Diabetes Obes Metab       Date:  2022-06-20       Impact factor: 6.408

2.  Year-long effects of COVID-19 restrictions on glycemic control and body composition in patients with glucose intolerance in Japan: A single-center retrospective study.

Authors:  Ryo Tsukaguchi; Takaaki Murakami; Satoshi Yoshiji; Kenichiro Shide; Yoshihito Fujita; Masahito Ogura; Nobuya Inagaki
Journal:  J Diabetes Investig       Date:  2022-08-18       Impact factor: 3.681

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.